Cosmo Pharmaceuticals
Market Cap
CHF1.0b
Last Updated
2019/11/20 20:59 UTC
Data Sources
Company Financials +
Executive Summary
Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, develops, manufactures, and distributes products for gastroenterology and endoscopy worldwide.
Snowflake
Fundamentals
Exceptional growth potential with mediocre balance sheet.
Similar Companies
Share Price & News
How has Cosmo Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: COPN has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
-2.0%
COPN
1.0%
CH Pharmaceuticals
0.5%
CH Market
1 Year Return
-42.5%
COPN
11.9%
CH Pharmaceuticals
14.8%
CH Market
Return vs Industry: COPN underperformed the Swiss Pharmaceuticals industry which returned 11.9% over the past year.
Return vs Market: COPN underperformed the Swiss Market which returned 14.8% over the past year.
Shareholder returns
| COPN | Industry | Market | |
|---|---|---|---|
| 7 Day | -2.0% | 1.0% | 0.5% |
| 30 Day | -8.8% | 4.5% | 3.4% |
| 90 Day | -18.5% | 6.5% | 5.3% |
| 1 Year | -42.5%-42.5% | 22.2%11.9% | 20.4%14.8% |
| 3 Year | -60.0%-60.4% | 54.1%32.4% | 43.1%24.7% |
| 5 Year | -52.0%-53.0% | 27.2%2.4% | 35.1%13.6% |
Price Volatility Vs. Market
How volatile is Cosmo Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
6 days ago | Simply Wall St
Is Cosmo Pharmaceuticals (VTX:COPN) Using Debt Sensibly?1 month ago | Simply Wall St
Some Cosmo Pharmaceuticals (VTX:COPN) Shareholders Are Down 49%3 months ago | Simply Wall St
Is Cosmo Pharmaceuticals (VTX:COPN) Weighed On By Its Debt Load?Valuation
Is Cosmo Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
2.31x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: COPN (CHF70.1) is trading above our estimate of fair value (CHF12.47)
Significantly Below Fair Value: COPN is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: COPN is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.
PE vs Market: COPN is unprofitable, so we can't compare its PE Ratio to the Swiss market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate COPN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: COPN is good value based on its PB Ratio (2.3x) compared to the CH Pharmaceuticals industry average (3.7x).
Next Steps
Future Growth
How is Cosmo Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
80.8%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: COPN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (3.3%).
Earnings vs Market: COPN is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: COPN's is expected to become profitable in the next 3 years.
Revenue vs Market: COPN's revenue (47.5% per year) is forecast to grow faster than the Swiss market (3.5% per year).
High Growth Revenue: COPN's revenue (47.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: COPN's Return on Equity is forecast to be high in 3 years time (28%)
Next Steps
Past Performance
How has Cosmo Pharmaceuticals performed over the past 5 years?
-61.8%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: COPN has high quality earnings.
Growing Profit Margin: COPN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: COPN is unprofitable, and losses have increased over the past 5 years at a rate of -61.8% per year.
Accelerating Growth: Unable to compare COPN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: COPN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-0.9%).
Return on Equity
High ROE: COPN has a negative Return on Equity (-7.68%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is Cosmo Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: COPN's short term assets (€351.6M) exceeds its short term liabilities (€16.4M)
Long Term Liabilities: COPN's short term assets (€351.6M) exceeds its long term liabilities (174.0M)
Debt to Equity History and Analysis
Debt Level: COPN's debt to equity ratio (38.9%) is considered satisfactory.
Reducing Debt: COPN's debt to equity ratio has increased from 1.2% to 38.9% over the past 5 years.
Debt Coverage: COPN's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: Insufficient data to determine if COPN's interest payments on its debt are well covered by EBIT.
Balance Sheet
Inventory Level: COPN has a low level of unsold assets or inventory.
Debt Coverage by Assets: COPN's debt is covered by short term assets (assets are 2.2x debt).
Next Steps
Dividend
What is Cosmo Pharmaceuticals's current dividend yield, its reliability and sustainability?
1.08%
Forecast Dividend Yield
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate COPN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate COPN's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if COPN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if COPN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: COPN is not paying a notable dividend for the Swiss market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of COPN's dividend in 3 years as they are not forecast to pay a notable one for the Swiss market.
Next Steps
Management
What is the CEO of Cosmo Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?
6.9yrs
Average management tenure
CEO
Alessandro Della Chà (56yo)
5.7yrs
Tenure
€1,671,169
Compensation
Mr. Alessandro E. Della Chà, LL.M, has been the Chief Executive Officer of Cosmo Pharmaceuticals N.V. (formerly Cosmo Pharmaceuticals S.p.A) since March 27, 2014 and also has been its Executive Director si ...
CEO Compensation Analysis
Compensation vs Market: Alessandro's total compensation ($USD0.00) is below average for companies of similar size in the Swiss market ($USD969.53K).
Compensation vs Earnings: Alessandro's compensation has been consistent with company performance over the past year.
Management Age and Tenure
6.9yrs
Average Tenure
63yo
Average Age
Experienced Management: COPN's management team is seasoned and experienced (6.9 years average tenure).
Board Age and Tenure
10.7yrs
Average Tenure
62yo
Average Age
Experienced Board: COPN's board of directors are seasoned and experienced ( 10.7 years average tenure).
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Management Team
Massimo Pedrani (65yo)
Head of Generics Business Development
- Tenure: 0yrs
Blake Boland (59yo)
Chief Sales Officer
- Tenure: 3.1yrs
Chris Tanner (68yo)
Head of Transactions Office & Executive Director
- Tenure: 13.8yrs
- Compensation: €780.65k
Roberto Villa (76yo)
Chief Manufacturing Officer
- Tenure: 0yrs
Luigi Moro (68yo)
Chief Scientific Officer
- Tenure: 20.2yrs
Mauro Ajani (64yo)
Founder & Chairman
- Tenure: 7.6yrs
- Compensation: €1.45m
Giuseppe Cipriano (62yo)
Chief Operating Officer
- Tenure: 18.8yrs
Alessandro Della Chà (56yo)
CEO & Executive Director
- Tenure: 5.7yrs
- Compensation: €1.67m
Davide Malavasi (46yo)
Technical Director
- Tenure: 8.2yrs
Niall Donnelly (45yo)
CFO & Head of Investor Relations
- Tenure: 3.4yrs
Board Members
Dieter Enkelmann (60yo)
Non-Executive Director
- Tenure: 13.8yrs
- Compensation: €155.78k
William Sandborn
Member of Scientific Advisory Board
- Tenure: 0yrs
Chris Tanner (68yo)
Head of Transactions Office & Executive Director
- Tenure: 13.8yrs
- Compensation: €780.65k
Mauro Ajani (64yo)
Founder & Chairman
- Tenure: 7.6yrs
- Compensation: €1.45m
Geert D’Haens
Member of Scientific Advisory Board
- Tenure: 0yrs
Alessandro Della Chà (56yo)
CEO & Executive Director
- Tenure: 5.7yrs
- Compensation: €1.67m
Silvio Danese
Member of Scientific Advisory Board
- Tenure: 0yrs
Maria Roncarolo (65yo)
Non-Executive Director
- Tenure: 7.6yrs
- Compensation: €155.78k
Ralf Kiesslich
Member of Scientific Advisory Board
- Tenure: 0yrs
Kevin Donovan (60yo)
Non-Executive Director
- Tenure: 3.7yrs
- Compensation: €140.40k
Company Information
Cosmo Pharmaceuticals N.V.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Cosmo Pharmaceuticals N.V.
- Ticker: COPN
- Exchange: SWX
- Founded: 1997
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: CHF1.031b
- Shares outstanding: 14.62m
- Website: https://www.cosmopharma.com
Number of Employees
Location
- Cosmo Pharmaceuticals N.V.
- Riverside II
- Sir John Rogerson’s Quay
- Dublin
- Co. Dublin
- 2
- Ireland
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| COPN | SWX (SIX Swiss Exchange) | Yes | New Common Shares | CH | CHF | Mar 2007 |
| C43 | DB (Deutsche Boerse AG) | Yes | New Common Shares | DE | EUR | Mar 2007 |
| CMOP.F | OTCPK (Pink Sheets LLC) | Yes | New Common Shares | US | USD | Mar 2007 |
| COPNZ | BATS-CHIXE (BATS 'Chi-X Europe') | Yes | New Common Shares | GB | CHF | Mar 2007 |
| 0RGI | LSE (London Stock Exchange) | Yes | New Common Shares | GB | CHF | Mar 2007 |
Biography
Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, develops, manufactures, and distributes products for gastroenterology and endoscopy worldwide. It offers Lialda/Mezavant/Mesavancol and UCERI ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/11/20 20:59 |
| End of Day Share Price | 2019/11/19 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.